A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients (PRESERVE)

November 2, 2026 updated by: Swedish Orphan Biovitrum

A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis

To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients

Study Overview

Detailed Description

The PRESERVE study is a Phase 3b, multicenter, single-arm, open-label clinical trial designed to explore the efficacy and safety of pegcetacoplan in preventing or delaying the recurrence of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) following kidney transplantation. Recurrence of these diseases after transplantation is common and can lead to graft dysfunction and loss. Pegcetacoplan is a complement C3/C3b inhibitor that has demonstrated activity in patients with native kidney disease and recurrent disease after transplantation. The study aims to assess whether initiating pegcetacoplan at the time of kidney transplantation, before recurrence occurs, may delay the recurrence and support long-term graft outcomes. Participants will receive pegcetacoplan in addition to standard post-transplant care and will be followed to evaluate disease recurrence, kidney function, graft outcomes, safety, and tolerability.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Pernambuco
      • Recife, Pernambuco, Brazil, 52010-010
        • Real Hospital Português
    • São Paulo
      • Botucatu, São Paulo, Brazil, 18618-970
        • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
      • São Paulo, São Paulo, Brazil, 05403-000
        • Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2R7
        • University of Alberta - Faculty of Medicine & Dentistry
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 1Y6
        • St. Paul's Hospital
    • Ontario
      • London, Ontario, Canada, N6A 5A5
        • London Health Sciences Centre (LHSC) - University Hospital
      • Toronto, Ontario, Canada, M5G 2C4
        • Toronto General Hospital
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • McGill University Health Centre Research Institute
      • Helsinki, Finland, 290
        • Helsinki University Central Hospital
    • Bas Rhin
      • Strasbourg, Bas Rhin, France, 67091
        • CHU Strasbourg - Nouvel Hôpital Civil
    • Haute Garonne
      • Toulouse, Haute Garonne, France, 31059
        • Hopital Rangueil
    • Herault
      • Montpellier, Herault, France, 34000
        • Hopital Lapeyronie pt
    • Nord
      • Lille, Nord, France, 59037
        • Hopital Claude Huriez - CHU Lille
    • Paris
      • Paris, Paris, France, 75015
        • Hôpital Necker - Enfants Malades
    • Rhone
      • Lyon, Rhone, France, 69437
        • Hopital Edouard Herriot - CHU Lyon
    • Lower Saxony
      • Hanover, Lower Saxony, Germany, 30625
        • Medizinische Hochschule Hannover
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Germany, 50937
        • Universitaetsklinikum Koeln
      • Essen, North Rhine-Westphalia, Germany, 45147
        • Universitaetsklinikum Essen
    • Bari
      • Bari, Bari, Italy, 70124
        • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
    • Bergamo
      • Bergamo, Bergamo, Italy, 24127
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
    • Roma
      • Roma, Roma, Italy, 165
        • Ospedale Pediatrico Bambino Gesù
      • Roma, Roma, Italy, 168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      • Riyadh, Saudi Arabia, 11211
        • King Faisal Specialist Hospital & Research Center
    • Barcelona
      • Barcelona, Barcelona, Spain, 8035
        • Hospital Universitari Vall d'Hebron - VHIR
    • La Coruña
      • A Coruña, La Coruña, Spain, 15006
        • Complejo Hospitalario Universitario A Coruña
    • Madrid
      • Madrid, Madrid, Spain, 28041
        • Hospital Universitario 12 de Octubre
    • Málaga
      • Málaga, Málaga, Spain, 29010
        • Hospital Regional Universitario de Malaga
    • Vizcaya
      • Barakaldo, Vizcaya, Spain, 48903
        • Hospital de Cruces
      • Lausanne, Switzerland, 1011
        • Centre Hospitalier Universitaire Vaudois (CHUV)
    • Greater London
      • London, Greater London, United Kingdom, NW3 2QG
        • Royal Free Hospital
      • London, Greater London, United Kingdom, W12 0HS
        • Hammersmith Hospital
    • Greater Manchester
      • Manchester, Greater Manchester, United Kingdom, M13 9WL
        • Manchester Royal Infirmary
    • Tyne & Wear
      • Newcastle upon Tyne, Tyne & Wear, United Kingdom, NE7 7DN
        • Freeman Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female patients with a diagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) who are planning to undergo kidney transplantation because of the disease.
  • Have a high risk of disease recurrence following kidney transplantation, based on either having a previous kidney allograft loss due to recurrence of C3G or primary IC-MPGN, or assessed as having a high risk by the investigator based on other clinical information.
  • Is fully vaccinated and up to date with their vaccinations against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B, in accordance with local guidelines, at the time of initiating pegcetacoplan.

Exclusion Criteria:

  • A known secondary cause for MPGN, including but not limited to monoclonal gammopathy of clinical significance, hepatitis B, hepatitis C, or autoimmune cryoglobulinemia.
  • History of invasive meningococcal disease.
  • History of malignancy, except for the following: cured basal or squamous cell skin cancer, curatively treated in situ disease, or currently malignancy-free and has been off-treatment for the malignancy for at least 5 years.
  • Hypersensitivity to pegcetacoplan or any of its excipients.
  • Known or suspected hereditary fructose intolerance.
  • Any other medical condition which, in the opinion of the Investigator, makes the participant unsuitable for inclusion.
  • Use of a complement inhibitor for the treatment of C3G or primary IC-MPGN within 1 month prior to the scheduled kidney transplantation surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pegcetacoplan

Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN

Dose amount based on age and weight Subcutaneous infusion twice-a-week. Adult participants aged 18 years or older at enrolment: 1080 mg

Adolescent participants aged 12 to 17 years at enrolment:

  • Weight ≥50 kg: 1080 mg
  • Weight 35 to <50 kg: 648 mg 1st dose, then 810 mg subsequently
  • Weight 30 to <35 kg: 540 mg for the first 2 doses, then 648 mg subsequently
Other Names:
  • APL-2
  • Aspaveli
  • Empaveli

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurrence of Clinically Significant Recurrent Disease
Time Frame: Within 2 years after kidney transplantation

Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy

Within 2 years after kidney transplantation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Onset of Clinically Significant Disease Recurrence
Time Frame: Up to 2 years after kidney transplantation

To explore the impact of pegcetacoplan on time to clinically significant recurrence of C3G or primary IC-MPGN after kidney transplantation

Up to 2 years after kidney transplantation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Director: Study Physician, Swedish Orphan Biovitrum AB (publ)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 21, 2027

Primary Completion (Estimated)

January 17, 2031

Study Completion (Estimated)

January 17, 2031

Study Registration Dates

First Submitted

October 21, 2026

First Submitted That Met QC Criteria

October 21, 2026

First Posted (Actual)

October 27, 2026

Study Record Updates

Last Update Posted (Actual)

November 4, 2026

Last Update Submitted That Met QC Criteria

November 2, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Sobi.PEGCET-404
  • 2026-526392-39-00 (Ctis)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers may request access to patient level data and related study documents.

All requests are evaluated by a cross functional panel of experts within Sobi. Patient level data will be anonymized and study documents, if applicable, will be redacted to protect the privacy of trial participants.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe